Nautilus Biotechnolgy, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $231.6M
- Price
- $1.82
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.14%
- Volume
- 6.6M
About
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Quick stats
Shares outstanding127.3M
Computed float80.3M
Float / shares63.1%
Cash runway (months)15.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001808805
Websitehttps://www.nautilus.bio
AI Summary
AI-generated1/9
minorbullishoperations update
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
Nautilus Biotechnology published a peer-reviewed study in Nature Methods demonstrating that its Iterative Mapping approach quantified 130 tau proteoform groups at the intact, single-molecule level — a view no other available technology has been shown to produce.
Technically, the assay used 12 site-specific antibodies to resolve up to 768 possible proteoform groups, detected proteoforms present at just 0.1% of a sample with a median coefficient of variation below 5.5%, and showed tau modifications accumulate in ordered, non-random sequences tied to disease biology.
The same validated approach is being extended to α-synuclein in Parkinson's disease and to AKT1, Nautilus' first oncology assay expected to enter the Early Access Program in late 2026, with roughly 20 proteoform assays targeted by mid-2028.
For a development-stage company whose platform is not yet commercially available, this is a scientific credibility and pipeline-validation milestone rather than a near-term financial catalyst; the tau assay is available now through the Early Access Program.
Red flags
- Human validation rests on a very small cohort: 5 ADRD patients and 2 cognitively normal individuals
- Nautilus' product platform is not yet commercially available and the company remains development-stage
- Late-2026 AKT1 Early Access entry and the ~20-assay-by-mid-2028 roadmap are forward-looking targets with acknowledged execution and delay risk